CARO
- Gender
- Women and men
- Age
- 18 years and older
- Trial type
- Observational
- Line of therapy
- Relapsed / refractory
- Phase
- Phase IV
What is this trial about?
The objective of this non-interventional study (NIS) is to evaluate treatment adherence among patients with multiple myeloma (MM) who have received at least one prior therapy and are being treated with carfilzomib.
Detailed description
The CARO study is an observational study in which patients receive a specific approved medication, and the study focuses solely on assessing treatment adherence and persistence. In this case, the study includes patients who have already received treatment but now require further therapy. The study follows patients receiving treatment with carfilzomib in combination with various medications.
Trial sites
5 trial sites in Germany are listed.
Universitätsklinikum Augsburg
Stenglinstraße 2, 86156 Augsburg
Active, not recruitingCentrum für Hämatologie und Onkologie Bethanien
60389 Frankfurt
Status unknownAGAPLESION Frankfurter Diakonie Kliniken gGmbH
Frankfurt am Main
RecruitingCentrum für Hämatologie und Onkologie Bethanien
RecruitingHämatologisch-Onkologische Schwerpunktpraxis in Würzburg & Kitzingen
Active, not recruiting
This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time.
- Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
- PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine
This description is based on the public trial registry (NCT02970747) and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.